Monocyte/macrophages may exert prominent roles in macrophage activation syndrome.

ABSTRACT: Secondary Hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening complication mostly occurs in adult patients with rheumatic disease, infection or lymphoma. To adequately steer treatment, clear discrimination of sHLH entities is essential. We aimed to discriminate serum biomarkers which can separate MAS from EBV associated HLH (EBV-HLH) and Lymphoma associated HLH (L-HLH) adequately. Samples from patients aged > 15 diagnosed with sHLH were analyzed using Luminex Multiple Assays (34-plex for pre-2022; 11-plex for post-2022). 209 patients were divided into three cohorts due to change of Luminex kits. Among 86 patients enrolled pre-2021, 45 patients enrolled in 2021-2022, and 78 patients enrolled post-2022. Clinical data and serum biomarkers were analyzed among MAS, EBV-HLH and L-HLH

SUBMITTER: Yin D 

PROVIDER: S-EPMC12672717 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature